| Title |
Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab
|
|---|---|
| Published in |
Journal of Neuro-Oncology, October 2015
|
| DOI | 10.1007/s11060-015-1977-9 |
| Pubmed ID | |
| Authors |
C. Frenard, L. Peuvrel, M. Saint Jean, A. Brocard, A. C. Knol, J. M. Nguyen, A. Khammari, G. Quereux, B. Dreno |
| Abstract |
Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy on brain metastases. To assess the development of brain metastases under ipilimumab and identify clinical, histological or evolving criteria related to the appearance of these metastases. A retrospective study was conducted in 52 patients treated with 4 cycles of ipilimumab 3 mg/kg every 3 weeks for unresectable stage III or stage IV melanoma between January 2011 and July 2013 in a Department of Dermato-Oncology. As no data has been find in the literature, the results were compared to our other cohort of patients treated with vemurafenib during the same period. Ten patients (21.7 %) developed brain metastases under ipilimumab in a median time of 6.58 months after treatment initiation. The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site. The median survival after diagnosis of brain metastases was of 2.5 months. There was no significant difference with vemurafenib-treated patients in terms of incidence rate of brain metastasis, time of development and survival after diagnosis of cerebral metastases. This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 3% |
| Unknown | 30 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 4 | 13% |
| Other | 3 | 10% |
| Student > Bachelor | 3 | 10% |
| Researcher | 3 | 10% |
| Student > Doctoral Student | 2 | 6% |
| Other | 7 | 23% |
| Unknown | 9 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 39% |
| Biochemistry, Genetics and Molecular Biology | 4 | 13% |
| Veterinary Science and Veterinary Medicine | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Other | 2 | 6% |
| Unknown | 10 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2015.
All research outputs
#15,349,419
of 22,831,537 outputs
Outputs from Journal of Neuro-Oncology
#1,946
of 2,970 outputs
Outputs of similar age
#166,888
of 284,642 outputs
Outputs of similar age from Journal of Neuro-Oncology
#32
of 75 outputs
Altmetric has tracked 22,831,537 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,970 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,642 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.